Trial Search Results

Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood

The purpose of this study is to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood in a smart menstrual pad. In other words, can the investigators detect the high risk strains of the human papilloma virus (HPV) that are associated with cervical cancer in self-collected menstrual blood, as an alternative to collecting vaginal swabs.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Diagnostic Test: Menstrual Blood Analysis (Menstrual Blood Analysis)

Eligibility


Inclusion Criteria:

   - Women in the age group 18-45 and

   - who are menstruating and

   - who have been tested HR-HPV positive and

   - who can commit to have protected sex using condoms if they change sexual partners in
   the time frame from self-collection and provider collected samples.

Exclusion Criteria:

   - Women younger than 18 years old or older than 45 years old or who are post menopausal
   or not menstruating regularly and who are not HR-HPV positive and who cannot commit to
   have protected sex using condoms if they change sexual partners in the time frame from
   self-collection and provider collected samples.

Ages Eligible for Study

18 Years - 45 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Klaira M Lerma, MPH
16507211562
Not Recruiting